GlassScriptPhysician profile
Yvanne Belanston
NPI 1316488240
$1,857.25
in general payments reported to CMS, 2019-2025
12 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $582 · 2024: $692 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $334.37 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $237.90 | 2023-2024 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $233.82 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $230.56 | 2025 | Invega |
| Grifols USA, LLC | $126.63 | 2022 | |
| Shield Therapeutics INC | $124.99 | 2023 | Accrufer |
| Genzyme Corporation | $122.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $116.43 | 2023 | Nuzyra |
| Biogen, INC. | $107.28 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.12 | 2025 | Lifevest |
| Janssen Scientific Affairs, LLC | $25.02 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvanne Belanston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.